Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies

• Published in: Journal of experimental & clinical cancer research Vol. 38; no. 1; pp. 464 - 17
• Main Authors: Baci, Denisa, Bruno, Antonino, Cascini, Caterina, Gallazzi, Matteo, Mortara, Lorenzo, Sessa, Fausto, Pelosi, Giuseppe, Albini, Adriana, Noonan, Douglas M.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.11.2019; BioMed Central; BMC
• Subjects: Acetylcarnitine - pharmacology; Analysis; Angiogenesis; Angiogenesis Inducing Agents - metabolism; Angioprevention; Animals; Anti-inflammatory agents; Antigens; Apoptosis - drug effects; Aspirin; Cancer cells; Cancer prevention; Carnitine; Cell cycle; Chemoprevention; Death; Development and progression; Dietary supplements; Down-Regulation; Endothelial growth factors; Endothelium; Health aspects; Human Umbilical Vein Endothelial Cells; Humans; Hyperplasia; Inflammation; Levocarnitine; Male; Mass spectrometry; Medical equipment industry; Mice; Mice, Nude; PC-3 Cells; Prevention; Prostate cancer; Prostatic hyperplasia; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Spectroscopy; Tumors; Xenograft Model Antitumor Assays; United States; Angiogenesis; Chemoprevention; Inflammation; Interception; Prostate cancer; Angioprevention; Carnitine

Prostate cancer (PCa) is a leading cause of cancer-related death in males worldwide. Exacerbated inflammation and angiogenesis have been largely demonstrated to contribute to PCa progression. Diverse naturally occurring compounds and dietary supplements are endowed with anti-oxidant, anti-inflammato...